ENDO: Timing of Vasomotor Symptoms Impacts CVD Risk

Share this content:
ENDO: Timing of Vasomotor Symptoms Impacts CVD Risk
ENDO: Timing of Vasomotor Symptoms Impacts CVD Risk

(HealthDay News) -- For women around the time of menopause, early vasomotor symptoms (VMS) correlate with lower levels of one marker of endothelial dysfunction, while persistent and late VMS correlate with one or more cardiovascular disease risk markers, according to a study presented at the annual meeting of The Endocrine Society, held from June 23 to 26 in Houston.

Emily Szmuilowicz, M.D., from Northwestern University in Chicago, and colleagues examined the correlation between VMS and circulating cardiovascular disease risk factors and blood pressure (BP) in the Women's Health Initiative Observational Study (WHI-OS). The status of VMS was classified as no VMS, early VMS (at menopause onset), late VMS (at time of enrollment to WHI-OS), or persistent VMS (at both times). The associations were examined in partially- and fully-adjusted models.

The researchers found that, in the partially-adjusted model, persistent VMS correlated with increased systolic and diastolic BP, while late VMS correlated with higher systolic BP, compared to no VMS. There was no association between early VMS and BP in either model. In the partially-adjusted model, persistent and late VMS correlated with higher white blood cell count. Persistent VMS correlated with higher glucose and insulin, and early VMS was linked to lower vascular cell adhesion molecule-1 in both models.

"Our study provides reassurance that the common experience of menopausal symptoms in early menopause is not associated with increases in blood pressure or other risk markers for cardiovascular disease," Szmuilowicz said in a statement.

More Information

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs